{"id":"W4396599772","doi":"10.1158/1538-7445.sabcs23-ps12-08","title":"Abstract PS12-08: MORPHEUS Hormone Receptor-Positive Breast Cancer: interim analysis of a Phase Ib/II, study of fulvestrant ± atezolizumab and abemaciclib triplet treatment in patients metastatic disease","year":2024,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Fulvestrant; Atezolizumab; Medicine; Oncology; Internal medicine; Cancer; Interim analysis; Breast cancer; Metastatic breast cancer; Disease; Estrogen receptor; Clinical trial; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005060178,0.002451113,0.003885113,0.0006242864,0.0005730213,0.001395769,0.001222038,0.001469379,0.004581891],"category_scores_gemma":[0.00229165,0.0008173274,0.00344139,0.0006107503,0.001194988,0.001006826,0.000613013,0.003930747,0.001271076],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001228615,"about_ca_system_score_gemma":0.002545118,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009625761,"about_ca_topic_score_gemma":0.001761122,"domain_scores_codex":[0.998269,0.0009873506,0.00007657219,0.0002015405,0.000142131,0.0003235007],"domain_scores_gemma":[0.9982854,0.0002964605,0.0003659367,0.0002197515,0.00009875406,0.0007336718],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9430784,0.01753234,0.004288471,0.000215059,0.001405463,0.0001058608,0.00006563085,0.001620463,0.009745592,0.0000897526,0.001808863,0.02004421],"study_design_scores_gemma":[0.4937295,0.4807735,0.01705078,0.00002383618,0.00157909,0.0002087548,0.00004269597,0.00127473,0.002916589,0.0002609545,0.002104384,0.00003525454],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9878567,0.001301754,0.0009223053,0.0004001937,0.000133479,0.00336022,0.004047773,0.0001590013,0.001818493],"genre_scores_gemma":[0.9797687,0.0007454763,0.002748506,0.0006945992,0.0002569513,0.005134509,0.007231649,0.00006330906,0.003356405],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005060178,"threshold_uncertainty_score":0.02676111,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06473927860091323,"score_gpt":0.4428545749237581,"score_spread":0.3781152963228449,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}